New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareCagrilintide vs Mazdutide

Cagrilintide vs Mazdutide

Side-by-side comparison of key properties, dosing, and research.

GLP-1 / Weight Loss Agonists
Cagrilintide
GLP-1 / Weight Loss Agonists
Mazdutide
Summary
Cagrilintide is a long-acting amylin analog developed by Novo Nordisk. Amylin is a peptide hormone co-secreted with insulin from pancreatic beta cells. Cagrilintide slows gastric emptying, suppresses glucagon, and reduces appetite via central amylin receptors. In combination with semaglutide (CagriSema), Phase 2 trials achieved approximately 15% body weight reduction. Phase 3 trials (REDEFINE program) are ongoing.
Mazdutide is a once-weekly GLP-1/glucagon dual receptor agonist developed by Innovent Biologics and Eli Lilly. Phase 2 trials in Chinese populations demonstrated up to 11.3% body weight reduction at 6 mg over 24 weeks. It also improves liver fat, glycemic control, and lipid profiles. Phase 3 trials are ongoing primarily in China.
Half-Life
~7–10 days
~7 days
Admin Route
SubQ
SubQ
Research
Typical Dose
0.16 mg → 0.3 mg → 0.6 mg → 1.2 mg → 2.4 mg
1.5 mg → 3 mg → 4.5 mg → 6 mg
Frequency
Once weekly
Once weekly
Key Benefits
  • ~15% body weight reduction in combination with semaglutide (CagriSema Phase 2)
  • Synergistic appetite suppression complementing GLP-1 receptor agonists
  • Reduces post-meal glucagon excursions improving glycemic control
  • Slows gastric emptying contributing to prolonged satiety
  • Once-weekly dosing via subcutaneous injection
  • Potential for greater weight loss than semaglutide monotherapy
  • Up to 11.3% body weight reduction at 24 weeks (Phase 2, 6 mg dose)
  • Significant reduction in liver fat content (NAFLD/MASH potential)
  • Improves HbA1c and fasting glucose in type 2 diabetes
  • Favorable lipid profile changes (reduced triglycerides)
  • Once-weekly subcutaneous dosing
  • Potential for superior weight loss vs GLP-1 monotherapy
Side Effects
  • Nausea (most common, especially during titration)
  • Vomiting
  • Decreased appetite
  • Diarrhea
  • +2 more
  • Nausea
  • Vomiting
  • Decreased appetite
  • Diarrhea
  • +3 more
Stacks With